Abstract
Objective
The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates. To explore the influencing factors on vaccine-induced effects, antibody responses to an inactivated SARS-CoV-2 vaccine in healthy individuals who were not previously infected by COVID-19 were assessed.
Methods
All subjects aged 18–60 years who did not have SARS-CoV-2 infection at the time of screening from June 19, 2021, to July 02, 2021, were approached for inclusion. All participants received two doses of inactivated SARS-CoV-2 vaccine. Serum IgM and IgG antibodies were detected using a commercial kit after the second dose of vaccination. A positive result was defined as 10 AU/mL or more and a negative result as less than 10 AU/mL. This retrospective study included 97 infection-naïve individuals (mean age 35.6 years; 37.1% male, 62.9% female).
Results
The seropositive rates of IgM and IgG antibody responses elicited after the second dose of inactivated SARS-CoV-2 vaccine were 3.1% and 74.2%, respectively. IgG antibody levels were significantly higher than IgM levels (P<0.0001). Sex had no effect on IgM and IgG antibody response after the second dose. The mean anti-IgG level in older persons (⩾42 years) was significantly lower than that of younger recipients. There was a significantly lower antibody level at > 42 days compared to that at 0–20 days (P<0.05) and 21–31 days (P<0.05) after the second dose.
Conclusion
IgG antibody response could be induced by inactivated SARS-CoV-2 vaccine in healthy individuals (>18 years), which can be influenced by age and detection time after the second dose of vaccination.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020,395(10223):514–523
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020,395(10223):507–513
Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus Infected Pneumonia. N Engl J Med, 2020,382(13):1199–1207
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet, 2020,395(10223):470–473
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020,382(8):727–733
Weekly epidemiological update on COVID-19 - 24 August 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on COVID-19—24-august-2021. [Accessed August 29, 2021].
Tezer H, Bedir Demirdağ T. Novel Coronavirus disease (COVID-19) in children. Turk J Med Sci, 2020,50(SI-1):592–603
Cruz MP, Santos E, Velázquez Cervantes MA, et al. COVID-19, a worldwide public health emergency. Rev Clin Esp (Barc), 2021,221(1):55–61
Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA, 2020,324(10):951–960
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 2020,396(10249):467–478
Wang F, Kream RM, Stefano GB. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Med Sci Monit, 2020,26:e924700
Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type 5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double blind, placebo-controlled, phase 2 trial. Lancet, 2020,396(10249):479–488
COVID-19 vaccine tracker and landscape. Available from:https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.[Accessed August 31, 2021].
Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 2021,384(5):403–416
Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 2020,383(27):2603–2615
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in 8 Brazil, South Africa, and the UK. Lancet, 2021,397(10269):99–111
Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis, 2021,21(1):39–51
Callaway E. Mix-and-match COVID vaccines trigger potent immune response. Nature, 2021,593(7860):491–491
Hou H, Wang T, Zhang B, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology, 2020,9(5):e01136
Doroftei B, Ciobica A, Ilie O-D, et al. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics (Basel), 2021,11(4):579
Salvagno GL, Henry BM, Piazza G di, et al. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID2019 mRNA BNT162b2 Vaccination. Diagnostics (Basel), 2021,11(5):832
Terpos E, Trougakos IP, Apostolakou F, et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol, 2021,96(7):E257–E259
Abu Jabal K, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill, 2021,26(6):2100096
Grupper A, Sharon N, Finn T, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol, 2021,16(7):103701042
Ward H, Cooke G, Whitaker M, et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. Available from: https://www.medrxiv.org/content/10.1101/2021.02.26.21252512v1.
Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med, 2021,385(10):875–884
Murin CD, Wilson IA, Ward AB. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nat Microbiol, 2019,4(5):734–747
Racine R, Winslow GM. IgM in microbial infections: taken for granted? Immunol Lett, 2009,125(2):79–85
Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun, 2021,12(1):3991
Röltgen K, Nielsen SCA, Arunachalam PS, et al. mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. medRxiv. 2021:2021.04.05.21254952
Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 2021,384(5):403–416
Omer SB, Yildirim I, Forman HP. Herd Immunity and Implications for SARS-CoV-2 Control. JAMA, 2020,324(20):2095–2096
Immunization coverage. Available from: https://www.who.int/news16room/fact-sheets/detail/immunization-coverage. [Accessed October 2, 2021].
Mallory ML, Lindesmith LC, Baric RS. Vaccination-induced herd immunity: Successes and challenges. J Allergy Clin Immunol, 2018,142(1):64–66
Kwok KO, Lai F, Wei WI, et al. Herd immunity-estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect, 2020,80(6):e32–e33
Dörschug A, Frickmann H, Schwanbeck J, et al. Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid Based Serological Assays. Diagnostics (Basel), 2021,11(3):426
Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ, 2021,374:n2015
Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis, 2021:ciab381
Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity, 2021, 54(2):205–210
Khodadadi L, Cheng Q, Radbruch A, et al. The Maintenance of Memory Plasma Cells. Front Immunol, 2019,10:721
Baumgarth N, Nikolich-Žugich J, Lee FEH, et al. Antibody Responses to SARS-CoV33 2: Let’s Stick to Known Knowns. J Immunol, 2020,205(9):2342–2350
Turner JS, O’Halloran JA, Kalaidina E, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature, 2021,596(7870):109–113
Author information
Authors and Affiliations
Corresponding authors
Additional information
Conflict of Interest Statement
We declare that we have no conflicts of interest.
This project was supported by grants from the Applied Basic Research Key Project of Wuhan Municipal Bureau of Science and Technology (No. 2020020601012218), the Fundamental Research Funds for the Central Universities (HUST COVID-19 Rapid Response Call No. 2020kfyXGYJ040), and National Natural Science Foundation of China (No. 81802090).
Rights and permissions
About this article
Cite this article
Banga Ndzouboukou, JL., Zhang, Yd., Lei, Q. et al. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. CURR MED SCI 41, 1081–1086 (2021). https://doi.org/10.1007/s11596-021-2461-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-021-2461-8